Cognitive deficits in patients with small cell lung cancer before and after chemotherapy

Meyers, Christina A.; Byrne, Kevin; Komaki, Ritsuko

doi:10.1016/0169-5002(95)00446-8

Cited by 136 publications

(80 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, Meyers et al (1995a) demonstrated that a 70 -80% of patients with small-cell lung cancer have memory deficits, 38% have deficits in executive functions, and 33% have impaired motor coordination before treatment is initiated.…”

Section: Chemotherapymentioning

confidence: 99%

Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target

2004

View full text Add to dashboard Cite

show abstract

Section: Chemotherapymentioning

confidence: 99%

Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target

2004

View full text Add to dashboard Cite

show abstract

“…As another example of the complexities of symptom assessment, cognitive function studies performed on untreated cancer patients suggest the subclustering of impairments as follows: memory, motor dexterity, and executive functions (frontal subcortical components) were impaired concurrently, whereas attention and psychomotor speed were not; 11 working memory (ability to process information and do multiple tasks) often was impaired, whereas hippocampal components of memory (retention and consolidation) were not. 12 Descriptive studies of the symptoms of cancer patients are far from comprehensive, but are consistent with the hypothesis that symptoms may have natural associations with each other that reflect the underlying mechanisms.…”

Section: Current Status Of Clinical Symptom Descriptionmentioning

confidence: 99%

Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?

Cleeland

Bennett

Dantzer

et al. 2003

Cancer

Self Cite

471

340

View full text Add to dashboard Cite

BACKGROUNDCancers and cancer treatments produce multiple symptoms that collectively cause a symptom burden for patients. These symptoms include pain, wasting, fatigue, cognitive impairment, anxiety, and depression, many of which co‐occur. There is growing recognition that at least some of these symptoms may share common biologic mechanisms.METHODSIn November 2001, basic and clinical scientists met to consider evidence for a cytokine‐immunologic model of symptom expression along with directions for future research.RESULTSThe characteristics of cytokine‐induced sickness behavior in animal models have much in common with those of symptomatic cancer patients. Sickness behavior refers to a set of physiologic and behavioral responses observed in animals after the administration of infectious or inflammatory agents or certain proinflammatory cytokines. In some cases, these responses can be prevented by cytokine antagonists. A combination of animal and human research suggests that several cancer‐related symptoms may involve the actions of proinflammatory cytokines.CONCLUSIONSBased on the similarities between cancer symptoms and sickness behavior, the authors discussed approaches to further test the implications of the relationship between inflammatory cytokines and symptoms for both symptom treatment and symptom prevention. Cancer 2003;97:2919–25. © 2003 American Cancer Society.DOI 10.1002/cncr.11382

show abstract

“…Observations suggesting that chemotherapy has harmful effects are supported by research on neurocognitive abilities in patients after chemotherapy for SCLC showing reduced baseline (as- sessed prior to radiotherapy) scores in neurocognitive tests in a significant number of examined patients. In most published studies, the numbers range between 15% and 70%, but some authors claim that baseline memory and cognitive abilities are significantly impaired in virtually all chemotherapy-exposed patients [4,5,26]. On the other hand, there is increasing evidence of the detrimental effects of WBRT.…”

Section: Discussionmentioning

confidence: 99%

“…PCI is also offered to patients with extensive disease to prolong survival and to reduce the incidence of brain metastases [3]. Nevertheless, the toxicity of this treatment remains an important concern, supported by evidence that whole brain irradiation (WBRT) and chemotherapy potentially induce neurocognitive impairment [4][5][6].…”

mentioning

confidence: 99%

Feasibility of reducing the irradiation dose in regions of active neurogenesis for prophylactic cranial irradiation in patients with small-cell lung cancer

Tarnawski

Michalecki²,

Blamek³

et al. 2011

neo

View full text Add to dashboard Cite

Prophylactic cranial irradiation (PCI) is performed on patients with limited or extensive small-cell lung cancer to reduce incidence of brain metastases and prolong survival. PCI may induce neurocognitive impairment. Decreasing irradiation of neural stem cells (NSC) might reduce PCI-induced toxicity. We tested the feasibility of reducing irradiation doses to neural stem cell (NSC) regions while maintaining prescribed doses to the planned target volume (PTV).Irradiation plans utilizing intensity-modulated radiotherapy (IMRT), helical TomoTherapy, and RapidArc for 10 consecutive lung cancer patients were evaluated. The dose distribution, dose-volume histograms, and dose homogeneity indexes were analyzed. Planned and actual dose distributions were compared by dosimetric analysis. Both helical tomotherapy and LINAC-based IMRT reduced the radiation dose to the NSC regions by approximately 45% while maintaining the full dose to the rest of brain. Measured dose distributions matched the planned dose distributions.Protecting the regions of active neurogenesis is technically feasible. Whether reducing the dose by 35% to 45% is sufficient to reduce treatment toxicity, however, can only be addressed in a randomized study. Further reducing the dose within the NSC region might also significantly decrease the dosage to the PTV.

show abstract

Cognitive deficits in patients with small cell lung cancer before and after chemotherapy

Cited by 136 publications

References 10 publications

Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target

Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target

Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?

Feasibility of reducing the irradiation dose in regions of active neurogenesis for prophylactic cranial irradiation in patients with small-cell lung cancer

Contact Info

Product

Resources

About